Epidemiology and Control of Mansonella Perstans Infection in Uganda
This study has been completed.
Sponsor:
DBL -Institute for Health Research and Development
Collaborator:
Vector control Division, Kampala, Uganda
Information provided by:
DBL -Institute for Health Research and Development
ClinicalTrials.gov Identifier:
NCT00215280
First received: September 21, 2005
Last updated: April 19, 2007
Last verified: April 2007
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Received Date ICMJE | September 21, 2005 | ||||
| Last Updated Date | April 19, 2007 | ||||
| Start Date ICMJE | November 2005 | ||||
| Primary Completion Date | Not Provided | ||||
| Current Primary Outcome Measures ICMJE |
|
||||
| Original Primary Outcome Measures ICMJE | Same as current | ||||
| Change History | Complete list of historical versions of study NCT00215280 on ClinicalTrials.gov Archive Site | ||||
| Current Secondary Outcome Measures ICMJE |
treatment effect on clinical manifestations | ||||
| Original Secondary Outcome Measures ICMJE | Same as current | ||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title ICMJE | Epidemiology and Control of Mansonella Perstans Infection in Uganda | ||||
| Official Title ICMJE | Studies on the Epidemiology and Control of Mansonella Perstans Infection in Uganda | ||||
| Brief Summary | Mansonella perstans (M. perstans) infection is widespread in Uganda. Knowledge about the epidemiology of this infection, and of the morbidity it induces is poor, and no effective treatment is available. The study aims at providing data on diagnostic, epidemiological, morbidity and treatment aspects of M. perstans infections in Uganda. |
||||
| Detailed Description | Overall objective: to investigate diagnostic, epidemiological and treatment aspects of M. perstans in Uganda with relevance to control Specific objectives:
|
||||
| Study Type ICMJE | Interventional | ||||
| Study Phase | Not Provided | ||||
| Study Design ICMJE | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Double-Blind Primary Purpose: Treatment |
||||
| Condition ICMJE |
|
||||
| Intervention ICMJE | Drug: ivermectin and albendazole | ||||
| Study Arm (s) | Not Provided | ||||
| Publications * |
|
||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Completed | ||||
| Enrollment ICMJE | 1000 | ||||
| Completion Date | February 2006 | ||||
| Primary Completion Date | Not Provided | ||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
| Gender | Both | ||||
| Ages | 5 Years and older | ||||
| Accepts Healthy Volunteers | Yes | ||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
| Location Countries ICMJE | Uganda | ||||
| Administrative Information | |||||
| NCT Number ICMJE | NCT00215280 | ||||
| Other Study ID Numbers ICMJE | MV917090205 | ||||
| Has Data Monitoring Committee | Not Provided | ||||
| Responsible Party | Not Provided | ||||
| Study Sponsor ICMJE | DBL -Institute for Health Research and Development | ||||
| Collaborators ICMJE | Vector control Division, Kampala, Uganda | ||||
| Investigators ICMJE |
|
||||
| Information Provided By | DBL -Institute for Health Research and Development | ||||
| Verification Date | April 2007 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||